Same receptor target, different compounds. Here's how the two main GHRH peptides compare on evidence, stability, dosing, and cost — based on published data.
Research context only. Neither compound is approved for general body composition use. This comparison is for educational purposes only.
Tesamorelin and sermorelin are both synthetic analogs of Growth Hormone Releasing Hormone (GHRH). They both stimulate the pituitary to produce GH. They're often mentioned in the same breath. But they're meaningfully different compounds with different evidence bases, different stability profiles, and different cost structures.
| Tesamorelin | Sermorelin | |
|---|---|---|
| Type | GHRH analog (modified) | GHRH fragment (1-29) |
| FDA status | Approved (Egrifta) | Previously approved, now discontinued Rx |
| Amino acids | 44 (full length + modification) | 29 (truncated fragment) |
| DPP-IV stability | High (N-terminal modification) | Lower (rapidly degraded) |
| Half-life | ~26 minutes | ~10–15 minutes |
| Primary evidence | Phase 3 RCTs (FDA approval) | Phase 2 / clinical use data |
| Visceral fat data | Robust (primary endpoint in trials) | Limited direct VAT measurement |
| Research peptide cost | Higher | Lower |
Both peptides bind the same GHRH receptor on pituitary somatotrophs. The difference is in how well they survive to get there.
Sermorelin is a synthetic version of the first 29 amino acids of GHRH — the minimum sequence needed for receptor binding and GH stimulation. It was FDA-approved in the 1990s as Geref for diagnosing GH deficiency and briefly for GH deficiency treatment, but the pharmaceutical manufacturer discontinued it (not for safety reasons — commercial reasons). It remains available as a research peptide.
Sermorelin's limitation is metabolic stability. Dipeptidyl peptidase IV (DPP-IV) cleaves the N-terminal Tyr-Ala bond quickly, degrading sermorelin rapidly in circulation. Its short half-life means it may require more precise timing or higher doses to achieve consistent GH stimulation.
Tesamorelin is the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. This single structural change protects against DPP-IV degradation, roughly doubling the effective half-life and improving the consistency of GH pulse stimulation.
Practical implication: More of the injected tesamorelin reaches its target receptor intact. This is reflected in the clinical data — tesamorelin's effects on IGF-1 and VAT in Phase 3 trials are more robust than what sermorelin studies have demonstrated.
This is the most important comparison point and the one most often glossed over. The evidence bases are not equivalent.
Tesamorelin has two Phase 3 randomized controlled trials (>800 participants total), FDA approval, and ongoing post-market safety data as Egrifta. Visceral fat reduction is a rigorously measured primary endpoint with MRI/CT quantification.
Sermorelin has Phase 2 data, clinical use data from its brief approval period, and a substantial body of off-label prescribing experience — particularly from anti-aging medicine. But no Phase 3 trials with hard endpoints comparable to tesamorelin's.
What this means practically: Sermorelin works — the GH stimulation mechanism is real and the clinical experience is substantial. But if you want the compound with the most rigorous evidence for visceral fat reduction specifically, tesamorelin is the only one with Phase 3 data and FDA review behind it.
| Parameter | Tesamorelin | Sermorelin |
|---|---|---|
| Typical dose | 1–2mg daily | 0.2–0.3mg daily (some use higher) |
| Timing | Fasted, before bed | Fasted, before bed |
| Frequency | Once daily | Once daily (sometimes split dosing) |
| Cycle length | 12–26 weeks | 3–6 months typical |
| Administration | SubQ injection | SubQ injection |
| Reconstitution | BAC water, 1–2mL per vial | BAC water, 1–2mL per vial |
As a research peptide, sermorelin is typically cheaper than tesamorelin — often significantly so. For researchers on a budget or those doing longer cycles, this is a real consideration.
Tesamorelin's price premium reflects its more complex synthesis (the N-terminal modification requires additional chemistry), its more robust evidence base, and its FDA-approved status as Egrifta driving quality expectations in the research peptide market.
The honest take: Both are legitimate GHRH peptides with real GH-stimulating effects. Tesamorelin is the better-studied compound with a harder evidence base. Sermorelin is a reasonable, more affordable alternative with substantial clinical use history. Neither has been proven superior in a direct head-to-head trial — because that trial hasn't been run.
COA-verified vendor pricing, promo codes, and reconstitution protocol.
Tesamorelin Pricing → Sermorelin Pricing →